Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2

Overview

Journal medRxiv

Date 2020 Nov 11

PMID 33173891

Citations 6

Authors

Jeromine Klingler

Svenja Weiss

Vincenza Itri

Xiaomei Liu

Kasopefoluwa Y Oguntuyo

Christian Stevens

Satoshi Ikegame

Chuan-Tien Hung

Gospel Enyindah-Asonye

Fatima Amanat

Ian Baine

Suzanne Arinsburg

Juan C Bandres

Erna Milunka Kojic

Jonathan Stoever

Denise Jurczyszak

Maria Bermudez-Gonzalez

Arthur Nadas

Sean Liu

Benhur Lee

Susan Zolla-Pazner

Catarina E Hioe

Affiliations

Soon will be listed here.

Abstract

Background: SARS-CoV-2 has infected millions of people globally. Virus infection requires the receptor-binding domain (RBD) of the spike protein. Although studies have demonstrated anti-spike and - RBD antibodies to be protective in animal models, and convalescent plasma as a promising therapeutic option, little is known about immunoglobulin (Ig) isotypes capable of blocking infection.

Methods: We studied spike- and RBD-specific Ig isotypes in convalescent and acute plasma/sera using a multiplex bead assay. We also determined virus neutralization activities in plasma, sera, and purified Ig fractions using a VSV pseudovirus assay.

Results: Spike- and RBD-specific IgM, IgG1, and IgA1 were produced by all or nearly all subjects at variable levels and detected early after infection. All samples displayed neutralizing activity. Regression analyses revealed that IgM and IgG1 contributed most to neutralization, consistent with IgM and IgG fractions' neutralization potency. IgA also exhibited neutralizing activity, but with lower potency.

Conclusion: IgG, IgM and IgA are critical components of convalescent plasma used for COVID-19 treatment.

Citing Articles

Anti-SARS-CoV-2 IgM Antibody Levels Measured by an In-House ELISA in a Convalescent Latin Population Persist over Time and Exhibit Neutralizing Capacity to Several Variants of Concern.

Espino A, Armina-Rodriguez A, Cardona P, Ocasio-Malave C, Alvarez L, Sariol C Diagnostics (Basel). 2024; 14(19).

PMID: 39410613 PMC: 11475847. DOI: 10.3390/diagnostics14192209.

Sensitivities of a Rapid Test Versus an ELISA Kit for Detecting Anti-SARS-CoV-2 IgM/IgG in Sera from an Egyptian Cohort.

Mohamed Bahgat M, Hassan Nasraa M, Nadeem R, Amer K, Hassan W, Elgarhy F Curr Microbiol. 2023; 81(1):24.

PMID: 38032503 DOI: 10.1007/s00284-023-03473-z.

Expression of mammalian proteins for diagnostics and therapeutics: a review.

Mark J, Lim C, Nordin F, Tye G Mol Biol Rep. 2022; 49(11):10593-10608.

PMID: 35674877 PMC: 9175168. DOI: 10.1007/s11033-022-07651-3.

Rapid Generation of In-House Serological Assays Is Comparable to Commercial Kits Critical for Early Response to Pandemics: A Case With SARS-CoV-2.

Auerswald H, Eng C, Lay S, In S, Eng S, Vo H Front Med (Lausanne). 2022; 9:864972.

PMID: 35602487 PMC: 9121123. DOI: 10.3389/fmed.2022.864972.

IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in Convalescent Plasma Pools.

Kober C, Manni S, Wolff S, Barnes T, Mukherjee S, Vogel T PLoS One. 2022; 17(1):e0262162.

PMID: 34982806 PMC: 8726489. DOI: 10.1371/journal.pone.0262162.

References

Mazzini L, Martinuzzi D, Hyseni I, Benincasa L, Molesti E, Casa E . Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. J Immunol Methods. 2020; 489:112937. PMC: 7695554. DOI: 10.1016/j.jim.2020.112937. View

Liu S, Lin H, Baine I, Wajnberg A, Gumprecht J, Rahman F . Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020; 26(11):1708-1713. DOI: 10.1038/s41591-020-1088-9. View

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

Atyeo C, Fischinger S, Zohar T, Slein M, Burke J, Loos C . Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. Immunity. 2020; 53(3):524-532.e4. PMC: 7392190. DOI: 10.1016/j.immuni.2020.07.020. View

Le T, Andreadakis Z, Kumar A, Roman R, Tollefsen S, Saville M . The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020; 19(5):305-306. DOI: 10.1038/d41573-020-00073-5. View

Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X . Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020; 584(7819):115-119. DOI: 10.1038/s41586-020-2380-z. View

Rogers T, Zhao F, Huang D, Beutler N, Burns A, He W . Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020; 369(6506):956-963. PMC: 7299280. DOI: 10.1126/science.abc7520. View

Shen C, Zhang M, Chen Y, Zhang L, Wang G, Chen J . An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency. Theranostics. 2019; 9(1):210-231. PMC: 6332795. DOI: 10.7150/thno.28434. View

Prevost J, Gasser R, Beaudoin-Bussieres G, Richard J, Duerr R, Laumaea A . Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. Cell Rep Med. 2020; 1(7):100126. PMC: 7524645. DOI: 10.1016/j.xcrm.2020.100126. View

10.

Horwitz J, Bar-On Y, Lu C, Fera D, Lockhart A, Lorenzi J . Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. Cell. 2017; 170(4):637-648.e10. PMC: 5554461. DOI: 10.1016/j.cell.2017.06.048. View

11.

Amanat F, Krammer F . SARS-CoV-2 Vaccines: Status Report. Immunity. 2020; 52(4):583-589. PMC: 7136867. DOI: 10.1016/j.immuni.2020.03.007. View

12.

Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

13.

Ibrahim D, Dulipsingh L, Zapatka L, Eadie R, Crowell R, Williams K . Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial. Infect Dis Ther. 2020; 9(4):913-926. PMC: 7502154. DOI: 10.1007/s40121-020-00341-2. View

14.

Weiss S, Klingler J, Hioe C, Amanat F, Baine I, Arinsburg S . A High-Throughput Assay for Circulating Antibodies Directed Against the S Protein of Severe Acute Respiratory Syndrome Coronavirus 2. J Infect Dis. 2020; 222(10):1629-1634. PMC: 7499578. DOI: 10.1093/infdis/jiaa531. View

15.

Amanat F, Stadlbauer D, Strohmeier S, Nguyen T, Chromikova V, McMahon M . A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020; 26(7):1033-1036. PMC: 8183627. DOI: 10.1038/s41591-020-0913-5. View

16.

Long Q, Tang X, Shi Q, Li Q, Deng H, Yuan J . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26(8):1200-1204. DOI: 10.1038/s41591-020-0965-6. View

17.

Oguntuyo K, Stevens C, Hung C, Ikegame S, Acklin J, Kowdle S . Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera. mBio. 2021; 12(1). PMC: 8545089. DOI: 10.1128/mBio.02492-20. View

18.

Meyer-Bahlburg A . B-1 cells as a source of IgA. Ann N Y Acad Sci. 2015; 1362:122-31. DOI: 10.1111/nyas.12801. View

19.

Padoan A, Sciacovelli L, Basso D, Negrini D, Zuin S, Cosma C . IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study. Clin Chim Acta. 2020; 507:164-166. PMC: 7194886. DOI: 10.1016/j.cca.2020.04.026. View

20.

Walls A, Park Y, Tortorici M, Wall A, McGuire A, Veesler D . Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 181(2):281-292.e6. PMC: 7102599. DOI: 10.1016/j.cell.2020.02.058. View